Last updated: June 7, 2026
Clindamycin Phosphate and Benzoyl Peroxide Suppliers: Who Manufactures the Drug, API Inputs, and Key Packaging Components?
What companies supply clindamycin phosphate and benzoyl peroxide active ingredients?
Clindamycin phosphate and benzoyl peroxide are commonly sourced from multiple global manufacturers depending on the dosage form (topical gel, lotion, foam, or combination kits). In the US, the supply chain typically splits into: (1) API manufacture (clindamycin phosphate; benzoyl peroxide), (2) drug product manufacturing (combination gel/lotion/kit), and (3) contract packaging.
Typical supplier categories
- API manufacturers
- Clindamycin phosphate (fermentation-derived antibiotic intermediate converted to the phosphate salt)
- Benzoyl peroxide (peroxide chemistry, often supplied as a formulated or controlled particle product)
- Drug product manufacturers
- Formulation and fill-finish of the combination product
- Excipients and raw-material suppliers
- Thickeners, surfactants, preservatives, solvents, and packaging components
High-volume, commonly recurring supplier base (global)
For combination products marketed in the US, the supplier pool usually includes major generic and specialty topical players plus contract manufacturers. The most material risk points for buyers are: benzoyl peroxide consistency (particle size, stability, assay) and clindamycin phosphate salt-spec compliance (moisture, polymorph/crystal form controls).
Which drug product manufacturers produce the clindamycin phosphate and benzoyl peroxide combination?
The combination is widely commercialized as a prescription topical for acne. Buyers typically see multiple NDA/ANDA holders and contract manufacturers behind the labeled product.
Drug product manufacturing structure
- ANDA holder / labeler: owns regulatory filing and typically controls release specs
- API supply: often multiple-qualified sources
- CMO fill-finish: manufactures bulk, then fills into tubes/jars, cartons, and labels
Commercial reality for sourcing
- If you are buying product or planning licensing, the practical path is to map:
(a) labeled product manufacturers
(b) their contract fill-finish partners
(c) API source diversity and approval history
Who supplies excipients and formulation components for this topical acne combination?
For clindamycin phosphate and benzoyl peroxide topical products, excipient supply is usually the bottleneck in supply shocks because these products require:
- controlled viscosity and spreadability (gel/lotion)
- stability against benzoyl peroxide degradation
- compatibility with clindamycin salt (pH window and solvent system)
Common excipient supply needs
- Thickeners and film formers (for gel or lotion viscosity)
- Surfactants and solubilizers
- Preservatives/antioxidants suited to benzoyl peroxide systems
- Water management and low-leaching packaging compatibility
- Packaging: aluminum or plastic tubes, caps, liners, valves (depending on dosage form)
What raw-material risks exist in sourcing benzoyl peroxide for topical combination products?
Benzoyl peroxide supply is sensitive to:
- decomposition handling and storage conditions
- particle size distribution (impacts texture and release)
- contamination control (metals, impurities affecting stability)
- peroxide hazard controls during manufacturing and logistics
For combo products, buyers screen suppliers for:
- assay and impurity profile consistency
- peroxide stability under the target shelf-life conditions
- traceability and change-control history
What suppliers are qualified for clindamycin phosphate API for topical combination use?
Clindamycin phosphate API sourcing is sensitive to:
- salt form and physicochemical specs
- moisture control and solid-state behavior
- impurity profiles and antibiotic-related regulatory thresholds
- controlled manufacturing and documentation systems
Purchasers usually require:
- full CoA package, batch traceability, and impurity reporting
- change-control commitments for manufacturing route or control strategy
How should procurement teams map supplier coverage and reduce single-source risk?
A defensible sourcing map for this combination typically requires:
- API multi-sourcing: at least two qualified clindamycin phosphate suppliers and two benzoyl peroxide suppliers (or equivalent controls)
- CMO redundancy: two fill-finish options for the same packaging format
- Packaging qualification: cap/liner/tube materials validated for peroxide compatibility
- Regulatory alignment: ensure supplier changes can be reported/approved under the applicable FDA CMC pathway
What are the key manufacturing and packaging requirements buyers should demand?
For combination topical gels/lotions, procurement should require:
- peroxide-compatible process controls and verified stability program
- controlled fill-finish conditions to reduce degradation or phase separation
- shelf-life data under ICH conditions for the finalized drug product
- packaging qualification studies (leachables/extractables and headspace controls if applicable)
Key Takeaways
- Supplier selection for clindamycin phosphate and benzoyl peroxide topical combinations should be approached as a three-layer map: API sources (both actives), drug product/CMO manufacturing, and packaging/liner compatibility.
- Benzoyl peroxide is the most supply- and stability-sensitive input; clindamycin phosphate salt-spec compliance is the most regulatory-sensitive input.
- Risk reduction comes from multi-sourcing across API and fill-finish plus packaging compatibility qualification.
FAQs
1) Do clindamycin phosphate and benzoyl peroxide come from the same suppliers for all combination products?
No. API supply is commonly multi-sourced and contract-manufacturing routes vary by NDA/ANDA holder.
2) What supplier qualifications matter most for benzoyl peroxide raw material?
Assay, impurities, particle size distribution, stability data, and peroxide-specific handling controls.
3) Can a contract manufacturer source both APIs directly?
Yes, some CMO models procure APIs, but regulatory responsibility and qualified source requirements usually remain with the labeler/ANDA holder.
4) What packaging components are most likely to cause compatibility issues?
Tube material, cap liner, and any elastomeric components exposed to benzoyl peroxide can affect stability and leachables.
5) What procurement documentation is typically required for API changes?
Batch CoAs, impurity profiles, solid-state/salt form controls, and validated change-control records aligned with CMC requirements.
References
- FDA. (n.d.). Pharmaceutical Quality Policy and current good manufacturing practice (CGMP) guidance and resources. U.S. Food and Drug Administration. https://www.fda.gov
- USP. (n.d.). General chapters and monographs for topical and active pharmaceutical ingredient quality standards. United States Pharmacopeia. https://www.usp.org
- ICH. (2003). ICH Q1A(R2): Stability testing of new drug substances and products. International Council for Harmonisation. https://www.ich.org
